ALKERMES | ALKS - 销售成本

金融业

USD

USD 2.49B

现金及等价物

USD 388.57M

USD 46.21M

USD 1.93B

USD 543.44M

USD 71.6M

股息收益率

0

USD -10.95M

USD 100.31M

1.8K

EPS每股收益

USD 0.29

股本和储备

USD 1.82B

USD 338.34M

债务利息支出

USD 12.28M

USD 11.94M

USD 285.82M

USD 5.63B

USD 49.34M

USD 326.44M

USD -10.95M

普通股股本

USD 165.61M

19.54

USD 100.74M

USD 384.5M

销售和管理费用

USD 187.2M

USD 196.63M

贸易债权人

USD 107.95M

应收帐款人

USD 334.03M

	销售成本	更改		日
AbbVie	USD 4.55B		757M	2025-12
Acadia Pharmaceuticals	USD 26.22M		4.58M	2025-12
ALKERMES	USD 46.21M		5.38M	2025-12
Amgen	USD 1.79B		128M	2025-12
Biogen	USD 810.1M		205.1M	2025-09
BioMarin Pharmaceutical	USD 161.56M		16.62M	2025-12
Bristol-Myers Squibb	USD 4.92B		657M	2025-12
Coherus Biosciences	USD 4.04M		324K	2025-12
Eli Lilly	USD 3.37B		363.7M	2025-12
Gilead Sciences	USD 1.62B		50M	2025-12
Heron Therapeutics	USD 11.12M		795K	2025-12
Ionis Pharmaceuticals	USD 8M		5.66M	2025-12
J&J	USD 7.97B		689M	2025-12
Merck	USD 3.32B		531M	2025-12
Minerva Neurosciences	386K		31K	2024-06
Nektar Therapeutics	USD 4.43M		5.3M	2024-09
Neurocrine Biosciences	USD 17.6M		246.4M	2025-12
Otsuka Holdings	JPY 192.74B		11.78B	2025-12
Pfizer	USD 6.29B		2.12B	2025-12
Regeneron Pharmaceuticals	USD 584.6M		63M	2025-12
Vertex Pharmaceuticals	USD 466M		51.2M	2025-12